Colchicine Plus Fosfomycin in Coronavirus Infection

Following Covid-19 outbreak, the scientific community focused on several alternatives for either preventing or therapeutically treating the illness. It is clear enough at this time that vaccines will not be available at least for the few months to come. An association between an antibiotic (Azithromycin) and an antimalarial drug (chloroquine) has already been tested. Safety and toxicity issues has raised some concern regarding Chloroquine doses needed to reach a therapeutic activity and some clinical trials must be aborted ( Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19) this study was registered with ClinicalTrials.gov, number NCT04323527) Some antibiotics can act as immunomodulators and particularly, Fosfomycin, has an immunomodulatory effect on human B-cell activation. Fosfomycin is considered an unique antibiotic which is chemically unrelated to any other known antibacterial agent. The effect of Fosfomycin on human T-cells function was yet studied and the inhibition of proliferation of human lymphocytes induced induced by polyclonal T-cell mitogens studied as a function of Fosfomycin dose